Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Equity Average (2020 - 2025)

Gain Therapeutics has reported Equity Average over the past 6 years, most recently at $4.8 million for Q3 2025.

  • Quarterly results put Equity Average at $4.8 million for Q3 2025, down 53.58% from a year ago — trailing twelve months through Sep 2025 was $4.8 million (down 53.58% YoY), and the annual figure for FY2024 was $10.0 million, down 36.68%.
  • Equity Average for Q3 2025 was $4.8 million at Gain Therapeutics, up from $4.7 million in the prior quarter.
  • Over the last five years, Equity Average for GANX hit a ceiling of $42.9 million in Q2 2021 and a floor of $4.7 million in Q2 2025.
  • Median Equity Average over the past 5 years was $13.1 million (2023), compared with a mean of $18.8 million.
  • Biggest five-year swings in Equity Average: skyrocketed 21236.09% in 2021 and later crashed 62.92% in 2023.
  • Gain Therapeutics' Equity Average stood at $36.2 million in 2021, then crashed by 42.59% to $20.8 million in 2022, then tumbled by 52.08% to $10.0 million in 2023, then dropped by 18.38% to $8.1 million in 2024, then plummeted by 40.89% to $4.8 million in 2025.
  • The last three reported values for Equity Average were $4.8 million (Q3 2025), $4.7 million (Q2 2025), and $6.6 million (Q1 2025) per Business Quant data.